Chimerix is now part of Jazz Pharmaceuticals
Chimerix announces FDA acceptance and Priority Review of New Drug Application for dordaviprone as treatment for recurrent H3 K27M-mutant diffuse glioma
Improving and Extending Lives
Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.
Expanded Access
For Healthcare professionals only
If you are interested in meeting with the Chimerix team, please feel free to reach out to us at [email protected] to coordinate an in-person meeting.
We look forward to connecting with you and answering any questions you may have about our programs.
